“Forbion Raises $2.6 Billion in Record Fundraise for European Biotech” — what this page in the network covers. Forbion, a leading European venture capital firm, has announced a massive $2.6 billion fundraise, marking its largest to date and one of the biggest in the region's recent history. The capital will be split across two new funds: Forbion Growth Opportunities III and Forbion Ventures VII, targeting later-stage and early-stage life sciences companies respectively. This fundraising underscores strong investor confidence in European biotech innovation, despite a challenging global market for venture capital.
The firm plans to back companies developing transformative medicines, with a focus on areas like oncology, rare diseases, and central nervous system disorders. Forbion's track record includes backing successful exits such as NewAmsterdam Pharma and Gyroscope Therapeutics. The new funds will enable Forbion to support companies from seed through IPO, reinforcing Europe's position as a hub for cutting-edge drug development. The full version stays on the original page, which this listing opens directly.